InvestSMART

Integral Diagnostics Limited (ASX:IDX)

ALERT: Price-sensitive ASX Announcement for IDX
Current share price for IDX : $2.060 -0.8 (-27.97%)+
Announcement
Release
26 Feb 2025 8:12AM
Price at Release
$2.860
Full Release
download
Summary
Integral Diagnostics Limited has reported its financial results for the half-year ended 31 December 2024, showing a revenue increase of 9.3% to $252.9 million and a significant improvement in EBITDA, which rose 210.0% to $35.1 million. Despite a loss of $396,000 attributed to owners, this reflects a substantial recovery from the previous year's loss of over $66 million. The company declared a fully franked interim dividend of 2.5 cents per share, continuing its commitment to shareholder returns amidst strategic expansions and the merger with Capitol Health Limited.
Key Points
  • Revenue increased by 9.3% to $252.9 million.
  • EBITDA rose 210.0% to $35.1 million.
  • Net loss for the half-year was $396,000 compared to a loss of $66.8 million last year.
  • A fully franked interim dividend of 2.5 cents per share was declared.
  • The company completed the acquisition of Capitol Health Limited.
  • Operating NPAT growth of 31.9% was reported before various costs.
  • Strong free cash flow growth of 22.7% was achieved.
  • Net debt to EBITDA ratio improved to 2.8x.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.